Literature DB >> 23398050

Risk factors for coughing in dogs with naturally acquired myxomatous mitral valve disease.

L Ferasin1, L Crews, D S Biller, K E Lamb, M Borgarelli.   

Abstract

BACKGROUND: Cough often is reported as the primary clinical sign of congestive heart failure (CHF) in dogs with chronic degenerative myxomatous mitral valve disease (MMVD). Concurrent airway disease and compression of the left mainstem bronchus by a large left atrium also have been proposed as potential causes of coughing in these patients.
OBJECTIVES: To investigate the association between the presence of coughing and different potential causes of cough, including CHF, abnormal radiographic airway pattern, and cardiomegaly in dogs affected by naturally acquired MMVD. ANIMALS: Two hundred six client-owned dogs.
METHODS: Retrospective analysis performed on medical records of dogs affected by MMVD that underwent full cardiac evaluation, including echocardiographic examination and thoracic radiography.
RESULTS: Univariate analyses showed that CHF is not a predictor of coughing (OR = 1.369; 0.723, 2.594), whereas abnormal radiographic airway pattern (OR = 3.650; 2.051, 6.496) and increased left atrial size observed radiographically (OR = 3.637; 1.904, 6.950) or echocardiographically (OR = 2.553; 1.436, 4.539) were significantly associated with coughing in dogs with MMVD. The same risk factors were significant in multivariate analyses. CONCLUSIONS AND CLINICAL IMPORTANCE: This study indicates that CHF is not significantly associated with coughing in dogs with MMVD. Instead, abnormal radiographic airway pattern and left atrial enlargement are associated with coughing in these patients. This important finding should be taken into account when considering diagnosis and clinical management of CHF in these dogs.
Copyright © 2013 by the American College of Veterinary Internal Medicine.

Entities:  

Mesh:

Year:  2013        PMID: 23398050     DOI: 10.1111/jvim.12039

Source DB:  PubMed          Journal:  J Vet Intern Med        ISSN: 0891-6640            Impact factor:   3.333


  10 in total

1.  Combination of the Modified Loop Technique and De Vega Annuloplasty in Dogs with Mitral Regurgitation.

Authors:  Takuma Aoki; Takashi Miyamoto; Naoyuki Fukamachi; Seiya Niimi; Yao Jingya; Yoshito Wakao
Journal:  Animals (Basel)       Date:  2022-06-27       Impact factor: 3.231

2.  Evaluation of bronchial narrowing in coughing dogs with heart murmurs using computed tomography.

Authors:  Matthieu Lebastard; Kevin Le Boedec; Mark Howes; Stephen Joslyn; Jodi S Matheson; Robert T O'Brien
Journal:  J Vet Intern Med       Date:  2021-04-03       Impact factor: 3.333

3.  Clinical severity score system in dogs with degenerative mitral valve disease.

Authors:  J López-Alvarez; J Elliott; D Pfeiffer; Y-M Chang; M Mattin; W Moonarmart; M J Hezzell; A Boswood
Journal:  J Vet Intern Med       Date:  2015 Mar-Apr       Impact factor: 3.333

4.  Prevalence and prognostic importance of pulmonary hypertension in dogs with myxomatous mitral valve disease.

Authors:  M Borgarelli; J Abbott; L Braz-Ruivo; D Chiavegato; S Crosara; K Lamb; I Ljungvall; M Poggi; R A Santilli; J Haggstrom
Journal:  J Vet Intern Med       Date:  2015 Mar-Apr       Impact factor: 3.333

5.  Factors associated with disease progression in dogs with presumed preclinical degenerative mitral valve disease attending primary care veterinary practices in the United Kingdom.

Authors:  Madeleine J Mattin; David C Brodbelt; David B Church; Adrian Boswood
Journal:  J Vet Intern Med       Date:  2018-12-18       Impact factor: 3.333

6.  Effect of temperature variation on hospital admissions and outcomes in dogs with myxomatous mitral valve disease and new onset pulmonary edema.

Authors:  Carlo Guglielmini; Marco Baron Toaldo; Alex Chiesa; Barbara Contiero; Michele Berlanda; Helen Poser
Journal:  PLoS One       Date:  2020-01-14       Impact factor: 3.240

7.  Longitudinal Analysis of Quality of Life, Clinical, Radiographic, Echocardiographic, and Laboratory Variables in Dogs with Preclinical Myxomatous Mitral Valve Disease Receiving Pimobendan or Placebo: The EPIC Study.

Authors:  A Boswood; S G Gordon; J Häggström; G Wess; R L Stepien; M A Oyama; B W Keene; J Bonagura; K A MacDonald; M Patteson; S Smith; P R Fox; K Sanderson; R Woolley; V Szatmári; P Menaut; W M Church; M L O'Sullivan; J-P Jaudon; J-G Kresken; J Rush; K A Barrett; S L Rosenthal; A B Saunders; I Ljungvall; M Deinert; E Bomassi; A H Estrada; M J Fernandez Del Palacio; N S Moise; J A Abbott; Y Fujii; A Spier; M W Luethy; R A Santilli; M Uechi; A Tidholm; C Schummer; P Watson
Journal:  J Vet Intern Med       Date:  2017-12-06       Impact factor: 3.333

Review 8.  Review of Diagnostic and Therapeutic Approach to Canine Myxomatous Mitral Valve Disease.

Authors:  Giulio Menciotti; Michele Borgarelli
Journal:  Vet Sci       Date:  2017-09-26

9.  Prognostic factors in dogs with presumed degenerative mitral valve disease attending primary-care veterinary practices in the United Kingdom.

Authors:  M J Mattin; A Boswood; D B Church; D C Brodbelt
Journal:  J Vet Intern Med       Date:  2018-10-24       Impact factor: 3.333

10.  Letter regarding "Evaluation of bronchial narrowing in coughing dogs with heart murmurs using computed tomography".

Authors:  Viktor Szatmári; Mark D Kittleson; Lynelle R Johnson; Rachel E Pollard; Manreet K Singh
Journal:  J Vet Intern Med       Date:  2021-09-29       Impact factor: 3.333

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.